Baekje Shenzhou Lottery Revenue

You can earn tens of thousands of yuan. Depends on how much money you put in.

Where the mantissa of the subscription number held by investors who participate in the online issuance of Baekje Shenzhou shares is the same as the above number, it is the winning number. There are 82,839 winning numbers * * *, and each winning number can only subscribe for 500 Baekje Shenzhou shares. Baekje is an innovative drug research and development enterprise. At present, the company has 1 1 self-developed drugs entering the clinical trial or commercialization stage, and three of them have been approved for marketing, namely, Baiyueze, Baizean and Baihuize. According to the data of IFind, in the third quarter of 20021,Bai Ze's revenue was 65.438+29.8 million yuan, Baiyue's revenue was 843 million yuan, and Baihui's revenue was 24.0988 million yuan. In terms of curative effect, the company's drugs are mainly used in cancer patients, and the comprehensive gross profit margin of the products is 87.9 1%. It is said that the company's performance should be very good with such a high gross profit margin, but the actual situation is that the company has suffered losses for five consecutive years, with a total loss of more than 30 billion yuan. The performance data of 202 1 is the forecast data in the prospectus. If you sign the subscription for Baekje Shenzhou new shares, please remember to pay in time before the afternoon of February 6th, 65438, otherwise the subscription will be deemed invalid.

I suggest you be cautious when investing in risky stocks! ! ! It only represents personal views, and the above is for reference only.

Baekje Shenzhou Biopharmaceutical Co., Ltd. was established on 20 17125 October. The legal representative is Wu (Wu), and the business scope of the company is: investing with the company's own funds; Investing in areas where foreign investment is allowed by the state according to law (limited to foreign-invested enterprises); Import and export of goods (except those involving special provisions on foreign investment access and license approval); Technology import and export; Biomedical technology research (except human stem cells and gene diagnosis and treatment technology); Biotechnology development services (rare and unique species in China, except for the development of wildlife resources protected by the state and originating in China); Biotechnology transfer services (rare and unique species in China, except for the development of wildlife resources protected by the state and originating in China); Drug research and development (except human stem cells and gene diagnosis and treatment technology); Drug research services; Medical research and experimental development (except human stem cells and gene diagnosis and treatment technology); Development and production of new anticancer drugs, cardiovascular and cerebrovascular drugs and nervous system drugs; Using bioengineering technology to produce new drugs; Biopharmaceutical manufacturing; Wait a minute.